J. Benedict (author) retweeted
🚨 $HIMS ACCELERATED ITS $1 BILLION INTERNATIONAL REVENUE TARGET BY YEARS!
One of the biggest takeaways from Hims & Hers' Q3 2026 earnings call that I haven't seen many people discussing is how quickly management's international growth expectations have accelerated
• February 2026: $1B in annual international revenue by 2030.
• August 2026: $1B in annual international revenue within three years (~2029).
• November 2026: Expects to surpass a $1B international annualized revenue run rate in 2027!
That is a MASSIVE acceleration from the company's original expectations.
International revenue reached $233.3M in Q3, growing 321% YoY and approximately 78% QoQ.
At that quarterly pace, Hims is already generating approximately $933M in annualized international revenue!
Management also raised its FY2026 international revenue outlook from at least $600M to at least $650M.
Now, it's important to recognize that much of the sequential acceleration came from including a full quarter of Eucalyptus revenue following the acquisition.
However, management also highlighted nearly 80% YoY growth in its international businesses excluding Eucalyptus.
J. Benedict (author) retweeted
🚨 BREAKING: BARCLAYS REITERATES $HIMS PRICE TARGET AT $35 - BUY RATING
J. Benedict (author) retweeted
$HIMS deliberately reduced marketing spend just enough to meet its revenue and adjusted EBITDA guidance.
They don't think it's worth burning unnecessary cash to promote its platform when it's due for an upgrade in Q4.
J. Benedict (author) retweeted
A drop in subscribers isn't good, but it's coming at a MUCH higher price point.
I think this is because $HIMS is pushing into higher value/revenue subs like weight loss and letting lower value customers in ED and hair loss.
Probably a good trade-off, but makes the numbers confusing without more detail.
$HIMS
The earnings "miss" needs to be understood with this context:
"Revenue grew 49% year-over-year, our second consecutive quarter of acceleration, with domestic revenue up 21% year-over-year and international revenue up more than 300% year-over-year. We delivered those results while intentionally pacing marketing spend ahead of several planned expansions to our platform in the fourth quarter, which we expect will set us up well heading into 2027."
J. Benedict (author) retweeted
This graph by @jbm_1992 says it all. $HIMS gross profit is going through the roof, but margins are collapsing
The knee jerk reaction is to read that as bad, but as Jeff said, investors can’t spend percentage margins
Investors can spend free cash flow on absolute dollar terms and if you can maximize that with lower margins, you should absolutely do it
J. Benedict (author) retweeted
🚨 BREAKING: CANACCORD GENUITY REITERATES $HIMS PRICE TARGET AT $40 - BUY RATING
J. Benedict (author) retweeted
🚨 $HIMS CEO Andrew Dudum says they will manufacture BPC-157 & TB-500 raw API at their peptide facility in Menlo Park, Californa
"For some of the newer peptides where the supply chains of the raw active ingredients like TB-500 and 157 are not really at the core quality that we would like to see, we will be manufacturing the raw APIs in our facilities in Menlo Park"
"Which I think actually positions us as really the only company in the U.S. capable of having that degree of quality oversight for these therapies"
🇺🇸🇺🇸🇺🇸
J. Benedict (author) retweeted
J. Benedict (author) retweeted
I am thrilled to join the Board & Advisory of Hims & Hers! The platform @AndrewDudum & Co. have built & are evolving for comprehensive telehealth incl. cardiovascular & hormone health & peptides (GLPs & more) w/start to finish (raw materials incl.) made in USA is making health & vigor available to everyone.
Our Q3 2026 results are now live!
We believe that in healthcare, whoever owns the customer relationship wins. We’re building an everyday digital health platform that millions of people can rely on, not just for a single treatment, but for the whole experience of getting and staying well. We’re making substantial progress: revenue growth accelerated to nearly 50% this quarter. Nearly three million people across four continents rely on us to access care.
Here’s how we’re continuing to push forward:
- Winning metabolic health. For many people, the relationship with Hims & Hers starts with weight loss, and we’re making care easier to access: one seamless experience across an assortment of weight loss medicines, including from @novonordisk and @EliLillyandCo, more flexible multi-month subscriptions that we’re preparing ahead of the new year, and an AI-native experience that now reaches the large majority of weight loss customers.
- Winning the major global markets: International revenue grew more than 4x year-over-year to $233 million, and is on track to reach a $1 billion annual run rate in 2027. Our reach now spans four continents, and we’re introducing the Hims & Hers brands to new markets, including Australia and Germany.
- Staying at the forefront of category expansion: Our platform helps us go deeper into complex care and launch specialties faster. For example, we launched controlled substances for the first time with injectable and oral TRT, and we’re excited to be launching our Peptides+ offering later this month.
We also announced today that @hubermanlab is joining our Board of Directors, and he’s also joining us as an advisor. I’ve spent a lot of time with Andrew over the past year and we’re in lock step on what matters: making the latest health innovations accessible and actionable for people everywhere.
This is how we’re building the platform that will redefine how people access healthcare. I can’t wait for you to see what comes next.
More on this quarter’s results, including important disclaimers: news.hims.com/newsroom/how-w…
J. Benedict (author) retweeted
$HIMS
$5 billion in revenue for 2027 is on the table
Market cap today: $6 billion
J. Benedict (author) retweeted
🚨 OUR OFFICIAL REVENUE PREDICTION FOR $HIMS Q3 2026
J. Benedict (author) retweeted
After what seems like the millionth trip to the doctor and pharmacy for something that SHOULD have been an AI or video call and an on-demand delivery, I’m convinced this should be $HIMS next BIG vertical.
KIDS
@AndrewDudum this needs to happen. It would improve the quality of life for millions of parents.
Happy to help launch it. @himshouse agree?
J. Benedict (author) retweeted
Hers has landed in Australia and expanded in the UK! 🇦🇺🇬🇧
When we launched @wearehers, it was because we knew women were long overdue for healthcare that was actually built for their lives. 8 years later, we’re reaching women all over the world. Not just with a single category or treatment, but with an entire health experience. One that’s simple. Personal. Designed with them at the center.
And we’re just scratching the surface of what we can do for women everywhere. Read more from Dr. Shepherd here: news.hims.com/newsroom/innov…
J. Benedict (author) retweeted
$HIMS
Eles & Elas CEO @AFecury says Hims should buy its way into Brazil
"Hims has bought its way into every new market."
"In Brazil, you'd be buying the rails, doctors, compounding pharmacy, nationwide logistics, installment payment, and the WhatsApp sales engine."
🚨 Brazil's 2nd-largest telehealth CEO on how $HIMS should enter Brazil
🇧🇷🇧🇷🇧🇷
FULL INTERVIEW
Abrahão Fecury (@AFecury) is co-founder and CEO of Eles & Elas, a Brazilian company that he says was built using "the Hims & Hers playbook". Eles & Elas is the 2nd largest telehealth company in Brazil, according to Fecury. Voy is #1.
$HIMS CEO Andrew Dudum has said during multiple earnings calls that Brazil is a market Hims might enter in the future 👀
This is our first episode with the CEO of a Brazilian telehealth. Thanks so much to Abrahão for coming on the show!!
04:51 - Revenue of R$4.5 million (~$1 million USD)
10:25 - Margins of each category
13:35 - Brazil healthcare 101
16:43 - 1 in 4 adults in Brazil has obesity
19:22 - Meta Ads brings in 80% of customers
24:30 - Why ANVISA banned Voy, then reversed it on August 5
28:32 - Voy "more than 10x Eles & Elas' revenue"
30:57 - Generic semaglutide margin is only 5-10%
34:26 - Lilly suing in Brazil too
35:30 - Paraguay shenanigans
40:38 - Why $HIMS should buy a telehealth to expand into Brazil
48:34 - Other countries in LatAm
Not financial, legal, or medical advice
J. Benedict (author) retweeted
$HIMS MIGHT SEE MASSIVE SUBSCRIBER INCREASE VERY SOON!
The company could see explosive subscriber growth in 2027.
Rising healthcare costs. Employers cutting benefits. Millions of people looking for affordable alternatives.
Add global expansion through Eucalyptus, and you have a company positioned to capture a massive wave of new customers.
Btw > This is WITHOUT peptides.
I not selling a single share…
J. Benedict (author) retweeted
oh sweet jesus $HIMS +10%
made in america peptides?! 🇺🇸
J. Benedict (author) retweeted
$HIMS $ENHA
🚨 RUMOR: Multiple sources now suggest peptide announcement could come as soon as October or November
The rollout could be phased - meaning all 6 peptides may not be moved to Category 1 at the same time
@bijans and OpenLoop CEO Jon Lensing, both recent guests on the Hims House podcast, have said they've heard similar timelines
Replying to @hypergrowth102 @Investinc_Intel
I talked to my contact earlier this week and they still think we get an announcement / press release before end of October for at least a few of the peptides that were discussed at PCAC meeting in late July.
The 6 that could get moved are BPC157, TB500, KPV, MotsC, Epitalon and Semax.
J. Benedict (author) retweeted
$HIMS continues to be one of the best buys in the entire market.
Extremely asymmetric.
The market sees the shift from compounded GLP-1s to branded treatments like $NVO’s as bearish because it will pressure margins in the short term.
I see the exact opposite.
It’s a massive validation of the $HIMS thesis.
Hims is sacrificing short-term margins to bring blockbuster weight-loss treatments onto its platform and attract a massive number of new customers.
Subscribers increased by 307K QoQ in Q2, although part of that growth came from the Eucalyptus acquisition.
But weight loss is just the entry point.
Customers will come to Hims for GLP-1s. Then Hims can cross-sell them higher-margin treatments across the rest of its platform.
And every new subscriber generates more health data.
More customers → more data → better personalization → better outcomes → more customers.
That flywheel will keep compounding.
$HIMS isn’t building a weight-loss company.
Weight loss is the customer acquisition engine for something much bigger.
























